TORONTO, JAN. 23, 2019 – Baylis Medical announced today the Canadian launch and first clinical use of its ExpanSure™ Transseptal Dilation System. The device combines a sheath and dilator into a single tool, and facilitates larger dilation compared to a standard fixed curve sheath.
The larger dilation optimizes left-heart procedures such as left-atrial appendage closures and balloon ablations for atrial fibrillation, which require a large sheath to cross the heart’s septum from the right atrium. The ExpanSure dilator aims to eliminate use of added force or the introduction of additional devices to achieve crossing, which are often necessary when a larger dilation area is needed. This could result in possible consequences for the patient.
“Baylis is pleased to offer a device uniquely designed to optimize transseptal access, allowing the physician’s primary focus to remain on delivering the necessary therapy to the patient,” said Neil Godara, Director of Research and Development at Baylis Medical.
A single, streamlined device without the traditional dilator-sheath transition also helps provide access in cases where a patient’s fibrotic septum makes transseptal access challenging. This was the case in one of the device’s first clinical uses.
“Following several attempts to introduce sheaths through the patient’s fibrous septum, access was only made possible by the ExpanSure dilator’s streamlined design. It provided the necessary access when other sheaths could not, while the larger dilation allowed the remainder of the procedure to take place,” said Cardiologist Dr. Peter Leong-Sit, Investigator with the Cardiac Arrhythmia Network of Canada (CANet).
Baylis is part of CANet’s network of industry partners, which provides important opportunities to validate its devices with leading physicians.
“Collaboration with companies like Baylis Medical are key to advancing the delivery of care for patients facing cardiac arrhythmia,” said Dr. Anthony Tang, CEO of CANet. “Together, we can ensure that physicians have access to meaningful solutions to the life-threatening issues patients may be facing.”
Development of the ExpanSure dilator was made possible by support from the Federal Economic Development Agency for Southern Ontario’s Advanced Manufacturing Fund (FedDev Ontario).
“In 2015, FedDev Ontario announced an investment of $15.2 million for Baylis Medical to accelerate the development and commercialization of leading-edge medical devices for use by doctors during heart procedures,” said the Honourable Navdeep Bains, Minister of Innovation, Science, and Economic Development and Minister responsible for FedDev Ontario. “Congratulations to Baylis Medical on the launch of an innovative product that will positively impact treatment of patients around the world and expand international markets for made-in-Canada technologies.”
The ExpanSure™ Transseptal Dilation System is expected to launch in the United States in early 2019.
About Baylis Medical
Baylis Medical is a world leader in the development and commercialization of high-performance cardiology devices that help physicians deliver life-changing therapies to patients. Headquartered in Canada, and with offices world-wide, our clinical solutions have been Improving the Lives of People Around the World for over 30 years. For more information, visit www.baylismedical.com and connect with us on Twitter, LinkedIn and Instagram.
PRM-00398 EN J-2 V-1 © Baylis Medical Company Inc., 2018. ExpanSure and the Baylis Medical logo are trademarks and/or registered trademarks of Baylis Medical Company Inc. in the USA and/or other countries. Patents Pending and/or issued. CAUTION: Federal Law (USA) restricts the use of these devices to or by the order of a physician. Before use, consult product labels and Instructions for Use for Indications for Use, Contraindications, Warnings, Precautions, Adverse Events and Directions for Use.
Thank you for subscription!